Expression of bFGF in malignant tumor and its clinical pathological significance
ZHAO Jian-fu1, XU Meng1, ZHAO Feng-zhi1, HU Peng-hui1, QUAN Qiang1, XIANG Jun-jian2, WANG Hong2
1. Department of Oncology, The First Affiliated Hospital, Guangzhou 510632, China;
2. Laboratory of Antibody Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
AIM: To detect basic fibroblast growth factor (bFGF) expression in clinical common malignant tumor (non-small-cell lung cancer,breast cancer, colon cancer and melanoma), and to identify relationship between the expression and tumor clinicopathological characteristics.METHODS: Immunohistochemical SP method was used to detect the expression of bFGF at protein level in 208 cases of paraffin-embedded tissue of primary malignant tumor patients (68 cases of lung cancer, 80 cases of breast carcinoma, 41 cases of colon cancer and 19 cases of melanoma).RESULTS: The bFGF protein expression levels were significantly higher in low differentiated non-small-cell lung cancer with lymph node metastasis, and were positively correlated with TNM. In addition, no significant influence of the bFGF protein expression on the patients with median survival period was observed. The protein expression of bFGF was higher in advanced breast cancer with lymph node metastasis and was commonly found in the middle/higher differentiated colon cancer with regional lymph node metastasis. Meanwhile, bFGF protein was highly expressed in advanced melanoma patients with lymph node metastasis.CONCLUSION: bFGF may participate in the process of occurrence and progression of malignant tumor. Expression of bFGF protein may be an effective parameter for evaluating metastasis and prognosis of malignant tumor.
Attoub S, Arafat K, Gelaude A, et al. Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis[J]. PLoS One, 2013, 8(1):e53087.
[2]
Montero A, Okada Y, Tomita M, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation[J]. J Clin invest, 2000, 105(8):1085-1093.
[3]
Presta M, Dell' Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis[J]. Cytokine Growth Factor Rev, 2005, 16(2):159-178.
[4]
Song S, Wientjes MG, Gan Y, et al. Fibroblast growth factors:an epigenetic mechanism of broad spectrum resistance to anticancer drugs[J]. Proc Natl Acad Sci U S A, 2000, 97(15):8658-8663.
[5]
Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer[J]. Cancer Res, 2002, 62(18):5210-5217.
[6]
Coldren CD, Helfrich BA, Witta SE, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines[J]. Mol Cancer Res, 2006, 4(8):521-528.
[7]
Marek L, Ware KE, Fritzsche A, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells[J]. Mol Pharmacol, 2009, 75(1):196-207.
[8]
Volm M, Koomagi R, Mattern J, et al. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas[J]. Eur J Cancer, 1997, 33(4):691-693.
[9]
Farhat FS, Tfayli A, Fakhruddin N, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer[J]. Crit Rev Oncol Hematol, 2012, 84(2):149-160.
[10]
Faridi A, Rudlowski C, Biesterfeld S, et al. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer[J]. Pathol Res Pract, 2002, 198(1):1-5.
[11]
Landriscina M, Cassano A, Ratto C, et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer[J]. Br J Cancer, 1998, 78(6):765-770.
[12]
Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenetic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression[J]. Am J Pathol, 2002, 160(3):1009-1019.
[13]
Birck A, Kirkin AF, Zeuthen J, et al. Expression of basic fibroblast growth factor and vascular endothelial factor in primary and metastatic melanoma from the same patients[J]. Melanoma Res, 1999, 9(4):375-381.
[14]
Giehl KA, Nagele U, Volkenandt M, et al. Protein expression of melanocyte growth factors(bFGF,SCF) and their receptors(FGFR-1, c-kit) in nevi and melanoma[J]. J Cutan Pathol, 2007:34(1):7-14.
Erdem H, Yildirim U, Uzunlar AK, et al. Relationship among expression of basic-fibroblast growth factor, MTDH/astrocyte elevated gene-1, adenomatous polyposis coli, matrix metalloproteinase 9,and COX-2 markers with prognostic factors in prostate carcinomas[J]. Niqer J Clin Pract, 2013, 16(4):418-423.
[18]
Villegas SN, Canham M, Brickman JM. FGF signaling as a mediator of lineage transitions-evidence from embryonic stem cell differentiation[J]. J Cell Biochem, 2010, 110(1):10-20.
[19]
Takeda M, Mikami T, Numata Y, et al. Papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression[J]. Am J Clin Pathol, 2013, 139(5):587-598.
[20]
Elagoz S, Egilmez R, Koyuncu A, et al. The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer[J]. Pathol Oncol Res, 2006, 12(1):21-27.
[21]
Chikazawa M, Lnoue K, Fudata S, et al. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder[J]. Pathobiology, 2008, 75(6):335-345.
Rykala J, Przbylowska K, Majsterek I, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables[J]. Pathol Oncol Res, 2011, 17(4):809-817.
